Oricula Therapeutics LLC is categorized under Wholesale Pharmaceutical Products in Seattle, WA and active since 2013.
Oricula Therapeutics LLC was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Wholesale Pharmaceutical Products business, which does work in the B2B market, and is classified as a Wholesale Pharmaceutical Products, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Malcolm Gleser at the company’s single location by writing to 474 39th Avenue East, Seattle, Washington WA 98112 or by phoning (206) 322-7526. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Oricula Therapeutics LLC |
| Contact Person: | Malcolm Gleser |
| Address: | 474 39th Avenue East, Seattle, Washington 98112 |
| Phone Number: | (206) 322-7526 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Wholesale Pharmaceutical Products |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Oricula Therapeutics LLC was started in 2013 to provide professional Wholesale Pharmaceutical Products under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Malcolm Gleser for inquiries that concern Oricula Therapeutics LLC by calling the company number (206) 322-7526, as your correspondence is most welcome. Additionally, the physical location of the single location of Oricula Therapeutics LLC can be found at the coordinates 47.624735,-122.282997 as well as the street address 474 39th Avenue East in Seattle, Washington 98112.
For its online presence, you may visit Oricula Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.